摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-{1-[3-(3-fluoro-4-methoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one | 1448717-58-5

中文名称
——
中文别名
——
英文名称
2-{1-[3-(3-fluoro-4-methoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one
英文别名
2-[1-[3-(3-fluoro-4-methoxyphenyl)azetidin-1-yl]ethyl]-7-(oxan-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one
2-{1-[3-(3-fluoro-4-methoxy-phenyl)-azetidin-1-yl]-ethyl}-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one化学式
CAS
1448717-58-5
化学式
C22H26FN5O3
mdl
——
分子量
427.479
InChiKey
LTAJEFJIXFLORZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    31
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    81
  • 氢给体数:
    1
  • 氢受体数:
    6

文献信息

  • [EN] PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE<br/>[FR] INHIBITEURS DE PDE9 COMPRENANT UN SQUELETTE IMIDAZOTRIAZINONE
    申请人:LUNDBECK & CO AS H
    公开号:WO2013110768A1
    公开(公告)日:2013-08-01
    This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula(l) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    这项发明涉及一类PDE9酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式(I)化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法,包括向受试者施用式(I)化合物的治疗有效量。本发明还提供了一种式(I)化合物,用于治疗患有精神障碍的受试者的方法,包括向受试者施用式(I)化合物的治疗有效量。
  • PDE9 inhibitors with imidazo triazinone backbone
    申请人:H. Lundbeck A/S
    公开号:US20150045348A1
    公开(公告)日:2015-02-12
    This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    这项发明涉及一类PDE9酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式(I)化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法,包括向受试者施用式(I)化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法,包括向受试者施用式(I)化合物的治疗有效量。
  • PDE9 Inhibitors with Imidazo Triazinone Backbone
    申请人:H. Lundbeck A/S
    公开号:US20160213674A1
    公开(公告)日:2016-07-28
    This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula (I) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
    本发明涉及一种PDE9酶抑制剂化合物。本发明提供一种制药组合物,包括本发明化合物的治疗有效量和药学上可接受的载体。本发明还提供了制备式(I)化合物的过程。本发明还提供了一种治疗神经退行性疾病的方法,包括向患者施用式(I)化合物的治疗有效量。本发明还提供了一种式(I)化合物,用于治疗精神障碍的方法,包括向患者施用式(I)化合物的治疗有效量。
  • PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE
    申请人:H. Lundbeck A/S
    公开号:EP2807163B1
    公开(公告)日:2017-03-22
  • PDE9- INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE
    申请人:H. Lundbeck A/S
    公开号:EP3178820B1
    公开(公告)日:2017-12-20
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯